Phoenix Bio

論文一覧

論文一覧

論文一覧

Antiviral effect of peptoids on hepatitis B virus infection in cell culture

    Murayama, A. Igarashi, H. Yamada, N. Aly, H. H. Molchanova, N. Lin, J. S. Nishitsuji, H. Shimotohno, K. Muramatsu, M. Barron, A. E. Kato, T.
    Antiviral Res. 2024 Mar;223:105821. doi: 10.1016/j.antiviral.2024.105821.

    The mitochondrial TSPO ligand Atriol mitigates metabolic-associated steatohepatitis by downregulating CXCL1

      Li, Y. Chen, L.b. Sottas, C. Raul, M. C. Patel, N. D. Bijja, J. R. Ahmed, S. K. Kapelanski-Lamoureux, A. Lazaris, A. Metrakos, P. Zambidis, A. Chopra, S. Li, M. Sugahara, G. Saito, T.
      Metabolism. 2024 Jun 11:155942. doi: 10.1016/j.metabol.2024.155942

      An allosteric inhibitor of sirtuin 2 blocks hepatitis B virus covalently closed circular DNA establishment and its transcriptional activity

        Tang, L. Remiszewski, S. Snedeker, A. Chiang, L. W. Shenk, T.
        Antiviral Res. 2024 Jun;226:105888. doi: 10.1016/j.antiviral.2024.105888.

        A Novel Approach to Orthotopic Hepatocyte Transplantation Engineered With Liver Hydrogel for Fibrotic Livers, Enhancing Cell-Cell Interaction and Angiogenesis

          Udagawa, D. Nagata, S. Yagi, H. Nishi, K. Morisaku, T. Adachi, S. Nakano, Y. Tanaka, M. Hori, S. Hasegawa, Y.. Abe, Y. Kitago, M. Kitagawa, Y.
          FEBS Lett. 2024 Jun;598(11):1354-1365. doi: 10.1002/1873-3468.14842.

          ヒト脂肪肝モデル細胞に関する論文のご案内

          弊社研究員の高橋より、ヒト脂肪肝モデル細胞(PXB-cells LA)に関する論文が発表されましたので、ご案内いたします。

          Development of an effective single-chain variable fragment recognizing a novel epitope in the hepatitis C virus E2 protein that restricts virus entry into hepatocytes

            Das, S. Behera, P. Shewale, D. J. Bodele, J. Das, S. Karande, A. A.
            Arch Virol. 2024 Apr 29;169(5):112. doi: 10.1007/s00705-024-06024-4.

            A novel, small anti-HBV compound reduces HBsAg and HBV-DNA by destabilizing HBV-RNA

              Watanabe, T. Hayashi, S. Zhaoyu, Y. Inada, H. Nagaoka, K. Tateyama, M. Tanaka, Y.
              J Gastroenterol. 2024 Apr;59(4):315-328. doi: 10.1007/s00535-023-02070-y. Epub 2024 Feb 5.

              Gut-liver microphysiological systems revealed potential crosstalk mechanism modulating drug metabolism

                Kurniawan, D. A. Leo, S. Inamatsu, M. Funaoka, S. Aihara, T. Aiko, M. Rei, I. Sakura, T. Arakawa, H. Kato, Y. Matsugi, T. Esashika, K. Shiraki, N. Kume, S. Shinha, K. Kimura, H. Nishikawa, M. Sakai, Y.
                PNAS Nexus. 2024 Feb 9;3(2):pgae070. doi: 10.1093/pnasnexus/pgae070. eCollection 2024 Feb.

                Multi-omics analysis of a fatty liver model using human hepatocyte chimeric mice

                  Ichikawa, A. Miki, D. Hayes, C. N. Teraoka, Y. Nakahara, H. Tateno, C. Ishida, Y. Chayama, K. Oka, S.
                  Sci Rep. 2024 Feb 9;14(1):3362. doi: 10.1038/s41598-024-53890-8.

                  Nucleos(t)ide analogs for hepatitis B virus infection differentially regulate the growth factor signaling in hepatocytes

                    Shimizu, R. Murai, K. Tanaka, K. Sato, Y. Takeda, N. Nakasyo, S. Shirasaki, T. Kawaguchi, K. Shimakami, T. Nio, K. Nakaya, Y. Kagiwada, H. Horimoto, K. Mizokami, M. Kaneko, S. Murata, K. Yamashita, T. Honda, M.
                    Hepatol Commun. 2024 Jan 5;8(1):e0351. doi: 10.1097/HC9.0000000000000351. eCollection 2024 Jan 1.

                    Hepatitis B virus evades the immune system by suppressing the NF-kappaB signaling pathway with DENND2A

                      Ide, M. Tabata, N. Yonemura, Y. Murai, K. Wang, Y. Ishida, A. Honda, M. Kaneko, S. Ito, S. Yanagawa, H.
                      Microbiol Spectr. 2024 Jan 19:e0378523. doi: 10.1128/spectrum.03785-23.

                      Chimeric mouse with humanized liver, an emerging tool for the drug development「創薬ツールとしてのヒト肝細胞キメラマウス」

                        Shimada, T.
                        Nihon Yakurigaku Zasshi. 2023;158(6):483-489. doi: 10.1254/fpj.23038.

                        A small molecule iCDM-34 identified by in silico screening suppresses HBV DNA through activation of aryl hydrocarbon receptor

                          Furutani, Y. Hirano, Y. Toguchi, M. Higuchi, S. Qin, X. Y. Yanaka, K. Sato-Shiozaki, Y. Takahashi, N. Sakai, M. Kongpracha, P. Suzuki, T. Dohmae, N. Kukimoto-Niino, M. Shirouzu, M. Nagamori, S. Suzuki, H. Kobayashi, K. Masaki, T. Koyama, H. Sekiba, K. Otsuka, M. Koike, K. Kohara, M. Kojima, S. Kakeya, H. Matsuura, T.
                          Cell Death Discov. 2023 Dec 22;9(1):467. doi: 10.1038/s41420-023-01755-w.

                          Induction of open-form bile canaliculus formation by hepatocytes for evaluation of biliary drug excretion

                            Arakawa, H. Nakazono, Y. Matsuoka, N. Hayashi, M. Shirasaka, Y. Hirao, A. Tamai, I.
                            Commun Biol. 2023 Aug 22;6(1):866. doi: 10.1038/s42003-023-05216-z.

                            Hepatocyte-targeted siTAZ therapy lowers liver fibrosis in NASH diet-fed chimeric mice with hepatocyte-humanized livers

                              Wang, X. Moore, M. P. Shi, H. Miyata, Y. Donnelly, S. K. Radiloff, D. R. Tabas, I.
                              Mol Ther Methods Clin Dev. 2023 Nov 23;31:101165. doi: 10.1016/j.omtm.2023.101165. eCollection 2023 Dec 14.

                              SRPKIN-1 as an inhibitor against hepatitis B virus blocking the viral particle formation and the early step of the viral infection

                                Li, X. Nakashima, K. Ito, M. Matsuda, M. Chida, T. Sekihara, K. Takahashi, H. Kato, T. Sawasaki, T. Suzuki, T.
                                Antiviral Res. 2023 Dec;220:105756. doi: 10.1016/j.antiviral.2023.105756. Epub 2023 Nov 20.

                                A versatile method to profile hepatitis B virus DNA integration

                                  Fukano, K. Wakae, K. Nao, N. Saito, M. Tsubota, A. Toyoshima, T. Aizaki, H. Iijima, H. Matsudaira, T. Kimura, M. Watashi, K. Sugiura, W. Muramatsu, M.
                                  Hepatol Commun. 2023 Dec 1;7(12):e0328. doi: 10.1097/HC9.0000000000000328. eCollection 2023 Dec 1.

                                  Quantitative prediction of CYP3A-mediated drug-drug interactions by correctly estimating fraction metabolized using human liver chimeric mice

                                    Miyake, T. Mochizuki, T. Nakagawa, T. Nakamura, M. Emoto, C. Komiyama, N. Hirabayashi, M. Tsuruta, S. Shimojo, T. Terao, K. Tachibana, T.
                                    Br J Pharmacol. 2023 Oct 23. doi: 10.1111/bph.16270.

                                    Development and characterization of secondary standards for nucleic acid amplification technology (NAAT) assays for detection of hepatitis E virus

                                      Fares-Gusmao, R. Jiang, Z. Subramaniam, S. Visser, B. J. Scott, A. Ishida, Y. Saito, T. Baylis, S. A. McGivern, D. R. H. E. V. Standard Calibration Study Group
                                      J Clin Virol. 2022 Dec;157:105325. doi: 10.1016/j.jcv.2022.105325.

                                      Functional involvement of endothelial lipase in hepatitis B virus infection

                                        Shirasaki, T. Murai, K. Ishida, A. Kuroki, K. Kawaguchi, K. Wang, Y. Yamanaka, S. Yasukawa, R. Kawasaki, N. Li, Y. Y. Shimakami, T. Sumiyadorj, A. Nio, K. Sugimoto, S. Orita, N. Takayama, H. Okada, H. Thi Bich, P. D. Iwabuchi, S. Hashimoto, S. Ide, M. Tabata, N. Ito, S. Matsushima, K. Yanagawa, H. Yamashita, T. Kaneko, S. Honda, M.
                                        Hepatol Commun. 2023 Aug 31;7(9):e0206.